Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

Saturday, March 2, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

- 80 to 100% of BE ABLE 1 responders maintained a response of at least 90% disease improvement (PASI90) over 60 weeks with bimekizumab

Corporate Communications

France Nivelle,Global Communications, UCB

Investor Relations

Antje Witte,Investor Relations, UCB

Brand Communications

Andrea Christopher,Immunology Communications, UCB

 

T +32.2.559.9178,france.nivelle@ucb.com  

T +32.2.559.94.14, antje.witte@ucb.com 

T +1.404.483.7329 andrea.christopher@ucb.com 

 

Laurent Schots,

Media Relations, UCB   

 

T+32.2.559.92.64, laurent.schots@ucb.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store